The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The possibility of using selinexor as a bridge to CAR-T therapy in myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses the value of selinexor in myeloma therapy, highlighting its potential to re-establish T-cell repertoires in immune-exhausted patients. Dr Richardson describes how selinexor can be used in combination with other agents as a bridge to CAR-T therapy. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
